Skip to main content
. 2024 Jun 5;9(7):890–902. doi: 10.1016/j.jacbts.2024.04.006

Figure 1.

Figure 1

TPHi Attenuates Pulmonary Arterial Hypertension in the SuHx Rat Model: Invasive Hemodynamic Measurements

(A) Experimental design. Three age-matched groups: 1) control (ConNx); 2) SuHx (injected with SU5416, 20 mg/kg per dose, subcutaneous, and then exposed to hypoxia for 3 weeks, followed by 6 weeks of room air); and 3) SuHx+TPHi (treated orally with TPHi [TPT-001, 25 mg/kg /day] for 5 weeks). (B to G) Invasive hemodynamic measurements performed 6 weeks after the end of hypoxia to assess the right ventricular systolic pressure (RVSP), right ventricular end-diastolic pressure (RVEDP), systolic blood pressure (SAP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and heart rate (HR). Mean ± SEM, n = 7-11, ANOVA–Bonferroni post hoc test. ∗∗∗P < 0.001.